Drug Discovery Stories

Section 1: Drug discovery techniques and Strategies1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application3. Hit Discovery from DNA-Encoded Chemical Libraries4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy5. Macrocyclization strategy in kinase drug discovery6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments8. A future battle, small molecule drugs for cancer stem cell targeted therapy9. Stem cell therapies for combating emerging and re-emerging viral infections10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?12. Selenium and small molecules: a symbiotic partnership13. Novel Combinations of CD33-Targeted Immunotherapies14. Novel payloads of antibody-drug conjugates15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines16. mRNA Vaccines: The Next Frontier in Disease Prevention17. Unravelling the drying techniques of protein biopharmaceuticalsSection 2: Drug discovery case studies18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-1920. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis30. Oliceridine (TRV-130): A Biased Agonist of the µ Opioid Receptor as a Novel Analgesic31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin33. Antidiabetic Drugs Targeted PPAR¿: From Full Agonists to Selective Modulators34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease